Literature DB >> 31825540

Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Andrea K Miyahira1, Adam Sharp2,3, Leigh Ellis4,5,6, Jennifer Jones7, Salma Kaochar8, H Benjamin Larman9, David A Quigley10,11, Huihui Ye12,13, Jonathan W Simons1, Kenneth J Pienta14,15,16, Howard R Soule1.   

Abstract

INTRODUCTION: The 2019 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Prostate Cancer Research: The Next Generation," was held 20 to 23 June, 2019, in Los Angeles, California.
METHODS: The CHPCA Meeting is an annual conference held by the Prostate Cancer Foundation, that is uniquely structured to stimulate intense discussion surrounding topics most critical to accelerating prostate cancer research and the discovery of new life-extending treatments for patients. The 7th Annual CHPCA Meeting was attended by 86 investigators and concentrated on many of the most promising new treatment opportunities and next-generation research technologies.
RESULTS: The topics of focus at the meeting included: new treatment strategies and novel agents for targeted therapies and precision medicine, new treatment strategies that may synergize with checkpoint immunotherapy, next-generation technologies that visualize tumor microenvironment (TME) and molecular pathology in situ, multi-omics and tumor heterogeneity using single cells, 3D and TME models, and the role of extracellular vesicles in cancer and their potential as biomarkers. DISCUSSION: This meeting report provides a comprehensive summary of the talks and discussions held at the 2019 CHPCA Meeting, for the purpose of globally disseminating this knowledge and ultimately accelerating new treatments and diagnostics for patients with prostate cancer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  artificial intelligence; cancer immunotherapy; precision medicine; therapeutics; tumor genomics

Mesh:

Year:  2019        PMID: 31825540      PMCID: PMC7301761          DOI: 10.1002/pros.23934

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  197 in total

1.  Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest.

Authors:  L C Huang; K C Clarkin; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

2.  Bacterial vesicles in marine ecosystems.

Authors:  Steven J Biller; Florence Schubotz; Sara E Roggensack; Anne W Thompson; Roger E Summons; Sallie W Chisholm
Journal:  Science       Date:  2014-01-10       Impact factor: 47.728

3.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Authors:  Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan
Journal:  J Clin Invest       Date:  2017-06-26       Impact factor: 14.808

4.  Nuclear pores protect genome integrity by assembling a premitotic and Mad1-dependent anaphase inhibitor.

Authors:  Veronica Rodriguez-Bravo; John Maciejowski; Jennifer Corona; Håkon Kirkeby Buch; Philippe Collin; Masato T Kanemaki; Jagesh V Shah; Prasad V Jallepalli
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

Review 6.  Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Sameek Roychowdhury; Sangeeta Goswami; Joseph E Ippolito; Saul J Priceman; Colin C Pritchard; Karen S Sfanos; Sumit K Subudhi; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2016-09-28       Impact factor: 4.104

7.  PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.

Authors:  Nisha Nagarsheth; Dongjun Peng; Ilona Kryczek; Ke Wu; Wei Li; Ende Zhao; Lili Zhao; Shuang Wei; Timothy Frankel; Linda Vatan; Wojciech Szeliga; Yali Dou; Scott Owens; Victor Marquez; Kaixiong Tao; Emina Huang; Guobin Wang; Weiping Zou
Journal:  Cancer Res       Date:  2015-11-13       Impact factor: 12.701

8.  Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Authors:  Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade
Journal:  Lancet Oncol       Date:  2017-12-14       Impact factor: 41.316

9.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Authors:  David A Quigley; Ha X Dang; Shuang G Zhao; Paul Lloyd; Rahul Aggarwal; Joshi J Alumkal; Adam Foye; Vishal Kothari; Marc D Perry; Adina M Bailey; Denise Playdle; Travis J Barnard; Li Zhang; Jin Zhang; Jack F Youngren; Marcin P Cieslik; Abhijit Parolia; Tomasz M Beer; George Thomas; Kim N Chi; Martin Gleave; Nathan A Lack; Amina Zoubeidi; Robert E Reiter; Matthew B Rettig; Owen Witte; Charles J Ryan; Lawrence Fong; Won Kim; Terence Friedlander; Jonathan Chou; Haolong Li; Rajdeep Das; Hui Li; Ruhollah Moussavi-Baygi; Hani Goodarzi; Luke A Gilbert; Primo N Lara; Christopher P Evans; Theodore C Goldstein; Joshua M Stuart; Scott A Tomlins; Daniel E Spratt; R Keira Cheetham; Donavan T Cheng; Kyle Farh; Julian S Gehring; Jörg Hakenberg; Arnold Liao; Philip G Febbo; John Shon; Brad Sickler; Serafim Batzoglou; Karen E Knudsen; Housheng H He; Jiaoti Huang; Alexander W Wyatt; Scott M Dehm; Alan Ashworth; Arul M Chinnaiyan; Christopher A Maher; Eric J Small; Felix Y Feng
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

10.  Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma.

Authors:  Tatyana Vagner; Cristiana Spinelli; Valentina R Minciacchi; Leonora Balaj; Mandana Zandian; Andrew Conley; Andries Zijlstra; Michael R Freeman; Francesca Demichelis; Subhajyoti De; Edwin M Posadas; Hisashi Tanaka; Dolores Di Vizio
Journal:  J Extracell Vesicles       Date:  2018-08-07
View more
  9 in total

Review 1.  Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.

Authors:  Andrea K Miyahira; Jelani C Zarif; Catherine C Coombs; Robert R Flavell; Joshua W Russo; Samir Zaidi; Di Zhao; Shuang G Zhao; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2021-11-03       Impact factor: 4.104

2.  HSA-miR-34a-5p regulates the SIRT1/TP53 axis in prostate cancer.

Authors:  Yongqin Wen; Huijie Huang; Bo Huang; Xiaomin Liao
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  Transcriptome Profiles Reveal a 12-Signature Metabolic Prediction Model and a Novel Role of Myo-Inositol Oxygenase in the Progression of Prostate Cancer.

Authors:  Wangrui Liu; Jianfeng Xiang; Xinrui Wu; Shiyin Wei; Haineng Huang; Yu Xiao; Bo Zhai; Tao Wang
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

Review 4.  Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances.

Authors:  Catarina Lourenço; Vera Constâncio; Rui Henrique; Ângela Carvalho; Carmen Jerónimo
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

5.  A Glycolysis-Related Five-Gene Signature Predicts Biochemical Recurrence-Free Survival in Patients With Prostate Adenocarcinoma.

Authors:  Zijun Xu; Lijuan Xu; Liping Liu; Hai Li; Jiewen Jin; Miaoguan Peng; Yanrui Huang; Haipeng Xiao; Yanbing Li; Hongyu Guan
Journal:  Front Oncol       Date:  2021-04-19       Impact factor: 6.244

Review 6.  Nanomaterials-Based Urinary Extracellular Vesicles Isolation and Detection for Non-invasive Auxiliary Diagnosis of Prostate Cancer.

Authors:  Na Wang; Shuai Yuan; Cheng Fang; Xiao Hu; Yu-Sen Zhang; Ling-Ling Zhang; Xian-Tao Zeng
Journal:  Front Med (Lausanne)       Date:  2022-01-14

7.  Role of lncRNA MIAT/miR-361-3p/CCAR2 in prostate cancer cells.

Authors:  Tao Feng; Chunyu Song; Zhiyong Wu; Ke Zhao; Shenglan Ye
Journal:  Open Med (Wars)       Date:  2022-09-28

Review 8.  Advances of Zinc Signaling Studies in Prostate Cancer.

Authors:  Dangdang Li; Daniel B Stovall; Wenmeng Wang; Guangchao Sui
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

9.  Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer.

Authors:  Santosh Kumar Singh; Jennifer B Gordetsky; Sejong Bae; Edward P Acosta; James W Lillard; Rajesh Singh
Journal:  Cells       Date:  2020-08-27       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.